KGKun Guo

Kun Guo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kun Guo has a total of 78 co-authors. Here are the top co-authors by number of shared publications:

  • Hongxia Cheng

    Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China

    8 shared publications
  • Dongmei Gao

    Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, China

    7 shared publications
  • Miaomiao Li

    Endoscopy Center, Zhongshan Hospital, Fudan University, Shanghai, China

    6 shared publications
  • Sikai Wang

    Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, China

    6 shared publications
  • Lu Sun

    Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Cancer Research Center, Institutes of Biomedical Sciences, Fudan University, Shanghai, China

    5 shared publications
  • Yilan Huang

    Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, China

    5 shared publications

Latest Publications

  • Open Access

    NLRP3 deficiency preserves hippocampal perineuronal nets and attenuates lipopolysaccharide-induced depressive-like behaviors in mice

    by Yuxi Liu, Guxin Shi, Xuewen Ge, Haoran Wu, Xinxia Chang, Kun Guo

    Background: Neuroinflammation and extracellular matrix remodeling are implicated in depression, but their relationship remains unclear. We examined associations among NLRP3 deficiency, hippocampal perineuronal net (PNN) measures, and depressive-like behaviors after lipopolysaccharide (LPS) administration in mice.,Methods: Wild-type (WT) and NLRP3 knockout (KO) mice received intraperitoneal LPS or PBS. Depressive-like behavior and locomotion were assessed using the open-field (OFT), tail-suspension (TST), and forced-swim (FST) tests. Hippocampal WFA-positive PNN profiles, PV and Iba-1 immunoreactivity, and aggrecan and HAPLN levels were quantified. Chondroitinase ABC (chABC) was used to test whether PNN disruption altered behavioral outcomes in LPS-treated KO mice.,Results: In WT mice, LPS reduced OFT center exploration and locomotion, increased TST and FST immobility, and lowered WFA-positive PNN measures in the dentate gyrus and CA1. These changes were generally prevented or absent in KO mice, although the genotype-by-treatment interaction for TST immobility was nonsignificant; PV and Iba-1 immunoreactivity varied by region. In the DG, LPS increased Iba-1 density in WT but not KO mice, whereas effects varied across hippocampal regions. Western-blot analyses showed LPS-associated reductions in aggrecan and HAPLN in WT mice but not in KO mice; differences between LPS-treated genotypes were not uniform. In LPS-treated KO mice, chABC reduced WFA-positive PNN and WFA-positive/PV-positive profiles and shifted OFT and FST outcomes toward WT control values; TST immobility did not differ.,Conclusions: NLRP3 deficiency was associated with preserved hippocampal PNN measures and attenuation of selected depressive-like behaviors after LPS. The chABC findings suggest that PNN integrity contributes to this phenotype.

  • Open Access

    Radiation induces an EGFR-dependent lactate-epigenetic program underlying synergy with EGFR inhibition

    by Hongxia Cheng, Lu Meng, Shilan Luo, Chenhui Zhao, Xiesong Luo, Jingdan Pang, Qingyu Jiang, Yanghai Xiong, Peiwen Zhu, Kun Guo, et al.

    Clinical studies have suggested a therapeutic synergy between EGFR-TKIs and radiotherapy; however, the underlying mechanisms remain incompletely understood, particularly in tumors harboring the acquired resistance mutation EGFR T790M. Using EGFR T790M-positive cell lines, patient-derived organoids (PDOs), and patient-derived xenograft (PDX) models, we systematically investigated radiation responses in EGFR T790M-mutant tumors. Metabolic profiling, protein interaction and phosphorylation analyses, enzyme activity assays, chromatin immunoprecipitation sequencing (ChIP-seq), and DNA damage repair assessments were performed to elucidate the molecular mechanisms of therapeutic synergy between EGFR-TKIs and radiotherapy. We show that EGFR T790M drives a radiation-amplified glycolytic program characterized by enhanced intracellular lactate accumulation. Radiation induces EGFR-dependent tyrosine phosphorylation and activation of lactate dehydrogenase A (LDHA), sustaining lactate production. Rather than being rapidly exported or oxidized, lactate is retained intracellularly and promotes histone H3 lysine lactylation (H3Kla) at promoter regions of DNA repair genes, establishing a repair-permissive chromatin state. This epigenetic priming enhances repair complex assembly, accelerates recruitment of repair factors to DNA double-strand breaks, and facilitates efficient DNA damage resolution. Genetic or pharmacological disruption of the LDHA-lactate axis impairs DNA repair and restores radiosensitivity. In EGFR T790M PDX models, targeting this metabolic pathway significantly enhances radiotherapy efficacy with acceptable toxicity. Our findings identify a previously unrecognized metabolic-epigenetic-repair axis through which EGFR T790M promotes radiotherapy resistance. This study redefines the functional role of EGFR T790M in radiation biology, provides mechanistic insight into the clinical synergy between EGFR inhibition and radiotherapy, and offers a rational framework for developing metabolism-informed combination radiotherapy strategies.

  • Open Access

    BNIP3-mediated mitophagy boosts the competitive growth of Lenvatinib-resistant cells via energy metabolism reprogramming in HCC

    by Sikai Wang, Hongxia Cheng, Miaomiao Li, Dongmei Gao, Haoran Wu, Shanshan Zhang, Yilan Huang, Kun Guo

    An increasing evidence supports that cell competition, a vital selection and quality control mechanism in multicellular organisms, is involved in tumorigenesis and development; however, the mechanistic contributions to the association between cell competition and tumor drug resistance remain ill-defined. In our study, based on a contructed lenvitinib-resistant hepatocellular carcinoma (HCC) cells display obvious competitive growth dominance over sensitive cells through reprogramming energy metabolism. Mechanistically, the hyperactivation of BCL2 interacting protein3 (BNIP3) -mediated mitophagy in lenvatinib-resistant HCC cells promotes glycolytic flux via shifting energy production from mitochondrial oxidative phosphorylation to glycolysis, by regulating AMP-activated protein kinase (AMPK) -enolase 2 (ENO2) signaling, which perpetually maintaining lenvatinib-resistant HCC cells’ competitive advantage over sensitive HCC cells. Of note, BNIP3 inhibition significantly sensitized the anti-tumor efficacy of lenvatinib in HCC. Our findings emphasize a vital role for BNIP3-AMPK-ENO2 signaling in maintaining the competitive outcome of lenvitinib-resistant HCC cells via regulating energy metabolism reprogramming; meanwhile, this work recognizes BNIP3 as a promising target to overcome HCC drug resistance.


  • Open Access

    1-Methyltryptophan treatment ameliorates high-fat diet-induced depression in mice through reversing changes in perineuronal nets

    by Juntao Hu, Shanshan Zhang, Haoran Wu, Leilei Wang, Yuwen Zhang, Hongyang Gao, Meihui Li, Hong Ren, Honglei Xiao, Kun Guo, et al.

    Depression and obesity are prevalent disorders with significant public health implications. In this study, we used a high-fat diet (HFD)-induced obese mouse model to investigate the mechanism underlying HFD-induced depression-like behaviors. HFD-induced obese mice exhibited depression-like behaviors and a reduction in hippocampus volume, which were reversed by treatment with an indoleamine 2,3-dioxygenase (IDO) inhibitor 1-methyltryptophan (1-MT). Interestingly, no changes in IDO levels were observed post-1-MT treatment, suggesting that other mechanisms may be involved in the anti-depressive effect of 1-MT. We further conducted RNA sequencing analysis to clarify the potential underlying mechanism of the anti-depressive effect of 1-MT in HFD-induced depressive mice and found a significant enrichment of shared differential genes in the extracellular matrix (ECM) organization pathway between the 1-MT-treated and untreated HFD-induced depressive mice. Therefore, we hypothesized that changes in ECM play a crucial role in the anti-depressive effect of 1-MT. To this end, we investigated perineuronal nets (PNNs), which are ECM assemblies that preferentially ensheath parvalbumin (PV)-positive interneurons and are involved in many abnormalities. We found that HFD is associated with excessive accumulation of PV-positive neurons and upregulation of PNNs, affecting synaptic transmission in PV-positive neurons and leading to glutamate-gamma-aminobutyric acid imbalances in the hippocampus. The 1-MT effectively reversed these changes, highlighting a PNN-related mechanism by which 1-MT exerts its anti-depressive effect.


  • HSP90a promotes the resistance to oxaliplatin in HCC through regulating IDH1-induced cell competition

    by Sikai Wang, Hongxia Cheng, Yilan Huang, Miaomiao Li, Dongmei Gao, Huaping Chen, Ruxiong Su, Kun Guo


  • Open Access

    BNIP3-mediated mitophagy boosts the competitive dominant growth of lenvatinib resistant cells via reprogramming energy metabolism in HCC

    by Sikai Wang, Hongxia Cheng, Miaomiao Li, Haoran Wu, Shanshan Zhang, Dongmei Gao, Yilan Huang, Kun Guo

    Although increasing studies has demonstrated that cell competition widely involved in the growth and homeostasis of multicellular organisms is closely linked to tumorigenesis and development, the mechanistic contributions to the association between tumor cell competition-driven heterogeneity and drug resistance remains ill-defined. In our study, lenvitinib-resistant hepatocellular carcinoma (HCC) cells display obviously competitive growth dominance against sensitive cells through reprogramming energy metabolism. Mechanistically, when BCL2 interacting protein3 (BNIP3) overexpression activates mitophagy activity in lenvatinib-resistant HCC cells, energy imbalance signal caused by reduced mitochondrial oxidative phosphorylation levels provokes the phosphorylation of AMP-activated protein kinase (AMPK) sensor; subsequently, enabled AMPK specifically targets enolase 2 (ENO2) to enhance glycolysis and eventually promots the competitive capacity and dominant growth. Of note, BNIP3 deficiency shows certain inhibition of cell competition outcome. Our findings emphasize a vital role for BNIP3-AMPK-ENO2 signaling in maintaining the competitive outcome of lenvitinib-resistant HCC cells via regulating energy metabolism; meanwhile this work recognaizes BNIP3 as a promising target to overcome HCC drug resistance.

  • Open Access

    HSF1 is involved in immunotherapeutic response through regulating APOJ/STAT3-mediated PD-L1 expression in hepatocellular carcinoma

    by Hongxia Cheng, Sikai Wang, Aidan Huang, Jing Ma, Dongmei Gao, Miaomiao Li, Huaping Chen, Kun Guo

    Hepatocellular cancer (HCC) is a serious illness with high prevalence and mortality throughout the whole world. For advanced HCC, immunotherapy is somewhat impactful and encouraging. Nevertheless, a substantial proportion of patients with advanced HCC are still unable to achieve a durable response, owing to heterogeneity from clonal variability and differential expression of the PD-1/PD-L1 axis. Recently, heat shock factor 1 (HSF1) is recognized as an important component of tumor immunotherapeutic response as well as related to PD-L1 expression in cancer. However, the mechanism of HSF1 regulating PD-L1 in cancer, especially in HCC, is still not fully clear. In this study, we observed the significantly positive correlation between HSF1 expression and PD-L1 expression in HCC samples; meanwhile combination expressions of HSF1 and PD-L1 served as the signature for predicting prognosis of patients with HCC. Mechanistically, HSF1 upregulated PD-L1 expression by inducing APOJ expression and activating STAT3 signaling pathway in HCC. In addition, we explored further the potential values of targeting the HSF1-APOJ-STAT3 axis against CD8+ T cells-mediated cancer cells cytotoxicity. These findings unveiled the important involvement of HSF1 in regulating PD-L1 expression in HCC as well as provided a novel invention component for improving the clinical response rate and efficacy of PD-1/PD-L1 blockade.


  • Nucleotide sugar transporter SLC35A2 is involved in promoting hepatocellular carcinoma metastasis by regulating cellular glycosylation

    by Hongxia Cheng, Sikai Wang, Dongmei Gao, Kangkang Yu, Huaping Chen, Yilan Huang, Miaomiao Li, Jubo Zhang, Kun Guo

    Purpose Recently, aberrant glycosylation has been recognized to be relate to malignant behaviors of cancer and outcomes of patients with various cancers. SLC35A2 plays an indispensable role on glycosylation as a nucleotide sugar transporter. However, effects of SLC35A2 on malignant behaviors of cancer cells and alteration of cancer cells surface glycosylation profiles are still not fully understood, particularly in hepatocellular carcinoma (HCC). Hence, from a glycosylation perspective, we investigated the effects of SLC35A2 on metastatic behaviors of HCC cells. Methods SLC35A2 expression in clinical samples and HCC cells was examined by immunohistochemical staining or Western blot/quantitative PCR and was regulated by RNA interference or vectors-mediated transfection. Effects of SLC35A2 expression alteration on metastatic behaviors and membrane glycan profile of HCC cells were observed by using respectively invasion, migration, cell adhesion assay, in vivo lung metastatic nude mouse model and lectins microarray. Co-location among proteins in HCC cells was observed by fluorescence microscope and detected by an in vitro co-immunoprecipitation assay. Results SLC35A2 was upregulated in HCC tissues, and is associated with poor prognosis of HCC patients. SLC35A2 expression alteration significantly affected the invasion, adhesion, metastasis and membrane glycan profile and led to the dysregulated expressions or glycosylation of cell adhesion-related molecules in HCC cells. Mechanistically, the maintenance of SLC35A2 activity is critical for the recruitment of the key galactosyltransferase B4GalT1, which is responsible for complex glycoconjugate and lactose biosynthesis, to Golgi apparatus in HCC cells. Conclusion SLC35A2 plays important roles in promoting HCC metastasis by regulating cellular glycosylation modification and inducing the cell adhesive ability of HCC cells.


  • Open Access

    Nucleotide Sugar Transporter SLC35A2 Is Involved In Promoting Metastatic Potential Of Hepatocellular Carcinoma

    by Hongxia Cheng, Sikai Wang, Kangkang Yu, Miaomiao Li, Jubo Zhang, Kun Guo

    Purpose Recently, aberrant glycosylation has been recognized to be relate to malignant behaviors of cancer and outcomes of patients in various cancers. SLC35A2 serves as a nucleotide sugar transporter and plays an indispensable role on glycosylation. However, effects of SLC35A2 on malignant behaviors of cancer cells and alteration of cancer cells surface glycosylation profile are still not fully understood, particularly in liver cancer. Hence, from an glycosylation prospective, we assessed the effects of SLC35A2 on malignant behaviors including metastatic potential of liver cancer cells. Methods SLC35A2 expression in HCC cells was examined by Western blot and quantitative PCR and was regulated by RNA interference or vectors-mediated transfection. Effects of SLC35A2 expression alteration on malignant behaviors and membrane glycan profile of HCC cells by using respectively invasion, migration, cell adhesion assay and lectins microarray. Co-location among proteins in HCC cells was observed by fluorescence microscope and detected by an in vitro co-immunoprecipitation assay. Results SLC35A2 was upregulated in HCC, and associated with poor prognosis of patients. SLC35A2 knockdown led to the decrese of invasion, adhesion, metastasis and the alteration of membrane glycan profile as well as the dysregulated expressions or glycosylation of cell adhesion-related molecules in HCC. Mechanistically, delivery of B4GalT1 to Golgi apparatus required the involvement of SLC35A2 in HCC cells and the site G266 was critical in maintaining the intact activity of B4GalT1. Conclusion SLC35A2 plays important roles in promoting HCC metastasis by regulating glycosylation modification on HCC cell surface and inducing cell adhesive ability.